[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biliary-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biliary-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,71,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100582259","phase-3-evaluating-the-safety-and-efficacy-of-duloxetine-in-the-prevention-of-post-endoscopic-retrograde-cholangiopancreatography-pancreatitis-100582259",false,"NCT06860984","Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Inclusion Criteria:\n\n* Age more than 18 years old.\n* Gender: Males and Females\n* Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.\n* Blood amylase and lipase levels before ERCP are within the normal limits\n\nExclusion Criteria:\n\n* Uncontrolled diabetes mellitus (DM)\n* Severe bleeding tendency\n* Impaired renal function (serum creatinine \\> 2 mg\u002FdL), (creatinine clearance \\\u003C30 ml\u002Fmin)\n* Patients with severe heart disease.\n* Subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.\n* Currently pregnant or nursing\n* Admission due to established pancreatitis before ECRP\n* Unwillingness to undergo ERCP.","ALL","18 Years","65 Years",{"count":19,"type":20},44,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.",[26],"Biliary Disease","RECRUITING","2026-08-16",{"date":30,"type":31},"2026-08-18","ACTUAL",{"date":33,"type":31},"2025-03-10",{"date":35,"type":20},"2027-07-10",{"name":37,"class":38},"Tanta University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100648018","development-and-prospective-validation-of-an-ai-based-diagnostic-model-for-hepato-pancreato-biliary-diseases-100648018","NCT07716670","Development and Prospective Validation of an AI-Based Diagnostic Model for Hepato-Pancreato-Biliary Diseases","Inclusion Criteria:\n\n* Age and Gender: Patients aged 18 to 75 years, of either sex.\n* Clinical Diagnosis Requirements: Suspected or confirmed hepatobiliary or pancreatic diseases (e.g., liver cancer, pancreatic cancer, cholangiocarcinoma, cirrhosis) based on preliminary clinical evaluation.\n* Ability to provide a complete medical history and symptoms for AI system interaction.\n* Cognitive and Physical Capacity:\n* Sufficient cognitive function to complete interactions with the AI multi-agent system independently (verified by Mini-Mental State Examination \\[MMSE\\] score ≥24).\n* Proficiency in Mandarin or English to ensure accurate communication with the system.\n* Consent and Compliance: Willingness to participate and provide written informed consent.\n* Ability to complete all study procedures, including physician consultations and follow-up assessments.\n* Clinical Workflow Compatibility: Scheduled for outpatient consultation at participating healthcare facilities.\n\nExclusion Criteria:\n\n* Patients with life-threatening conditions requiring immediate intervention (e.g., acute hepatic failure, severe hemorrhage).\n* Presence of severe cardiovascular or cerebrovascular diseases that may interfere with study participation.\n* Cognitive or Communication Barriers:\n* Cognitive impairment (MMSE score \\\u003C24) or language barriers preventing effective interaction with the AI system.\n* Psychiatric disorders or altered mental status affecting decision-making capacity.\n* Prior or Concurrent Participation:\n* Enrollment in other interventional clinical trials that may confound the study outcomes.\n* Current use of experimental diagnostic tools or AI systems outside the study protocol.\n* Technical or Logistical Constraints:\n* Inability to access or operate electronic devices required for AI system interaction (e.g., touchscreen terminals, mobile apps).\n* Lack of stable internet connectivity for system access.\n* Ethical or Legal Restrictions: Pregnancy or lactation (to avoid potential risks not directly related to the study).",true,{"count":48,"type":20},400,"4 Weeks","OBSERVATIONAL","The rapid advancement of artificial intelligence (AI) has expanded its applications in healthcare, particularly in diagnostic assistance, intelligent triage, and patient interaction. Hepatobiliary and pancreatic diseases (such as liver cancer, pancreatic cancer, cirrhosis) are characterized by insidious onset, rapid progression, low early-diagnosis rates, and poor prognosis. However, grassroots medical institutions in China face challenges including physician shortages, variable patient health literacy, and incomplete initial information collection, leading to high misdiagnosis\u002Fmissed diagnosis risks.\n\nRecent breakthroughs in large language models (LLMs) and multi-agent systems (MAS) offer new solutions. LLMs enable advanced natural language processing, while MAS coordinates specialized agents for complex decision-making. Integrating MAS with medical LLMs could create intelligent pre-consultation systems that systematically collect patient symptoms, risk factors, family history, and lifestyle data to enhance diagnostic efficiency.\n\nThis study aims to develop a MAS-based pre-consultation system for hepatobiliary-pancreatic diseases featuring four specialized agents (\"guidance agent,\" \"medical history agent,\" \"risk assessment agent,\" and \"summary generation agent\"). The system will simulate clinical reasoning to generate structured diagnostic reports for physicians.\n\nResearch Objectives:\n\nDevelop a specialized multi-agent framework combining LLMs to simulate clinical diagnostic logic and standardize symptom collection Enhance pre-consultation data integrity through intelligent dialogue focusing on key disease indicators Generate structured diagnostic summaries highlighting critical symptoms and risk factors Establish foundation for clinical validation and application through expert evaluation and user feedback This pre-diagnostic tool will assist physicians rather than replace clinical judgment, promoting safe, effective AI applications in early disease screening and tiered healthcare systems.",[53,26,54,55],"Hepatic Disease","Pancreas Disease","Artificial Intelligence (AI) in Diagnosis",[57,58,59,60],"hepatic disease","biliary disease","pancreas disease","artificial intelligence in diagnosis","NOT_YET_RECRUITING","2026-07-15",{"date":64,"type":31},"2026-07-21",{"date":66,"type":20},"2026-08-15",{"date":68,"type":20},"2026-11-30",{"name":70,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":50,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":39},"100450163","optimizing-the-evaluation-and-management-of-patients-with-suspected-choledocholithiasis-100450163","NCT05141916","Optimizing the Evaluation and Management of Patients With Suspected Choledocholithiasis","Inclusion Criteria:\n\n* Patients with suspected choledocholithiasis, regardless of probability\n* age 18 years old or older\n* able to give informed consent to involvement (in the prospective validation phase).\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent;\n* age \\\u003C 18 years;\n* suspected or proven cholangitis;\n* previous ERCP with sphincterotomy;\n* prior diagnosis or management of choledocholithiasis;\n* outpatient status;\n* out-of-province status (prohibiting full medical record access).",{"count":78,"type":20},2000,"6 Months","Choledocholithiasis (stone(s) in the common bile duct) is common. Untreated or missed, choledocholithiasis has high morbidity and mortality. Endoscopic retrograde cholangio-pancreatography (ERCP) is recognized as the first-line modality for management. While effective, ERCP is associated with adverse events. Thus, the selection of patients for ERCP should be accompanied by a high pre-test suspicion of choledocholithiasis.\n\nCholedocholithiasis is suspected based on clinical, biochemical and radiographic findings. The most relied-upon strategy for risk stratification of choledocholithiasis is based on guidelines from The American Society for Gastrointestinal Endoscopy (ASGE). In it, clinical predictors are defined as \"very strong\", \"strong\" or \"moderate\", and the presence of one or more of these is meant to suggest \"high\" or \"intermediate\" probability of choledocholithiasis.\n\nA knowledge gap exists in the performance characteristics of intermediate-probability criteria, where overall accuracy is \\\u003C50% from limited data. Patients in this group are recommended to a) undergo endoscopic ultrasound (EUS) or magnetic resonance cholangio-pancreatography (MRCP), b) undergo cholecystectomy with intra-operative cholangiography (IOC), or c) proceed directly to ERCP. At centres where EUS and MRCP are readily available, these are preferred options, as they are least invasive and sensitive; however, they are often unavailable. Thus, in clinical practice, a high proportion of intermediate-risk patients ultimately proceed directly to ERCP, where likelihood of benefit is only moderate, while procedural risk remains.\n\nThe role of liver enzyme changes has not been evaluated; however, dynamic changes may offer another method for evaluating patients at intermediate risk of CBD stones that is safe and available. Incorporation of dynamic liver enzymes may improve the test-performance characteristics of the existing framework.",[26,82],"Choledocholithiasis","2026-04-28",{"date":85,"type":31},"2026-04-29",{"date":87,"type":31},"2019-02-25",{"date":89,"type":20},"2029-06-30",{"name":91,"class":38},"University of Calgary",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":99,"targetDuration":101,"studyType":50,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":39},"100382434","calgary-registry-for-advanced-and-therapeutic-endoscopy-100382434","NCT04259580","Calgary Registry for Advanced and Therapeutic Endoscopy","CReATE","Inclusion Criteria:\n\n* any standard indication for ERCP, in the absence of standard contraindications;\n* age 18 years or over;\n* ability and willingness to give informed consent to be included in the registry and\u002For to involvement in one (or more) prospective sub-studies, or accompaniment by a surrogate who is willing and able to provide consent.\n\nExclusion Criteria:\n\n-none other than inverses of above.",{"count":100,"type":20},6000,"30 Days","The aim of the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is to be a high-fidelity prospective multi-centre registry. The study population consists of consecutive adult ERCP patients from September 2018 to August 2022. Informed consent is acquired for each patient. All relevant pre-procedural, procedural, peri-procedural and post-procedural data are captured in real time by a full-time third-party research assistant directly observing procedures. Outcomes are ascertained by comprehensive medical record review and patient phone interview 30 days after the index procedure. This registry also serves as a secure data collection platform for several currently recruiting prospective studies and randomized trials.",[26,104],"Pancreatic Diseases",{"date":85,"type":31},{"date":107,"type":31},"2018-09-01",{"date":109,"type":20},"2030-12-31",{"name":91,"class":38}]